SFE Investment Counsel lifted its stake in Johnson & Johnson (NYSE:JNJ) by 1.8% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 22,110 shares of the company’s stock after purchasing an additional 383 shares during the period. Johnson & Johnson accounts for approximately 1.1% of SFE Investment Counsel’s holdings, making the stock its 29th largest holding. SFE Investment Counsel’s holdings in Johnson & Johnson were worth $2,683,000 as of its most recent SEC filing.
Several other large investors also recently bought and sold shares of the company. Financial Gravity Wealth Inc. bought a new position in Johnson & Johnson during the first quarter worth about $105,000. WP Advisors LLC bought a new position in Johnson & Johnson during the second quarter worth about $108,000. FNY Investment Advisers LLC bought a new position in Johnson & Johnson during the second quarter worth about $117,000. Live Your Vision LLC lifted its holdings in Johnson & Johnson by 58.3% during the second quarter. Live Your Vision LLC now owns 1,363 shares of the company’s stock worth $172,000 after acquiring an additional 502 shares in the last quarter. Finally, Signition LP bought a new position in Johnson & Johnson during the first quarter worth about $204,000. Institutional investors and hedge funds own 66.60% of the company’s stock.
A number of analysts have recently commented on JNJ shares. Raymond James boosted their price target on Johnson & Johnson from $144.00 to $149.00 and gave the company an “outperform” rating in a report on Wednesday, October 17th. Credit Suisse Group boosted their price target on Johnson & Johnson from $149.00 to $152.00 and gave the company an “outperform” rating in a report on Wednesday, October 17th. Goldman Sachs Group upgraded Johnson & Johnson from a “sell” rating to a “neutral” rating in a report on Thursday, July 12th. Citigroup boosted their price target on Johnson & Johnson from $137.00 to $148.00 and gave the company a “neutral” rating in a report on Monday, October 22nd. Finally, ValuEngine upgraded Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Saturday, July 28th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $142.54.
NYSE:JNJ opened at $142.57 on Wednesday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.40 and a current ratio of 1.72. The stock has a market capitalization of $377.43 billion, a P/E ratio of 19.53, a P/E/G ratio of 2.20 and a beta of 0.58. Johnson & Johnson has a 52-week low of $118.62 and a 52-week high of $148.32.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 16th. The company reported $2.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.03 by $0.02. The business had revenue of $20.35 billion for the quarter, compared to the consensus estimate of $20.05 billion. Johnson & Johnson had a return on equity of 34.62% and a net margin of 1.89%. Johnson & Johnson’s quarterly revenue was up 3.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.90 earnings per share. On average, analysts anticipate that Johnson & Johnson will post 8.16 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 11th. Investors of record on Tuesday, November 27th will be given a $0.90 dividend. This represents a $3.60 dividend on an annualized basis and a dividend yield of 2.53%. The ex-dividend date is Monday, November 26th. Johnson & Johnson’s dividend payout ratio is currently 49.32%.
In related news, COO Michael E. Sneed sold 29,000 shares of Johnson & Johnson stock in a transaction dated Monday, August 27th. The stock was sold at an average price of $134.80, for a total value of $3,909,200.00. Following the sale, the chief operating officer now owns 59,124 shares of the company’s stock, valued at $7,969,915.20. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO Ronald A. Kapusta sold 7,899 shares of Johnson & Johnson stock in a transaction dated Friday, September 7th. The shares were sold at an average price of $137.18, for a total value of $1,083,584.82. Following the completion of the sale, the chief accounting officer now directly owns 25,725 shares in the company, valued at approximately $3,528,955.50. The disclosure for this sale can be found here. 0.22% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY NOTICE: “SFE Investment Counsel Buys 383 Shares of Johnson & Johnson (JNJ)” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US & international copyright legislation. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/11/07/sfe-investment-counsel-buys-383-shares-of-johnson-johnson-jnj.html.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Recommended Story: The Discount Rate – What You Need to Know
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.